Adrenocortical Carcinoma Molecular Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stratifying risk of recurrence in adrenocortical carcinoma (ACC) based on histological assessment are limited and do not reliably identify high-risk patients, leading to challenges in determining appropriate treatment courses.
Innovation Solution
Utilizing gene expression and methylation profiles, specifically evaluating the expression levels of BUB1B, PINK1, and G0S2, and the methylation status of G0S2, to characterize ACC and stratify patients into molecular subgroups (COC1, COC2, and COC3) that correlate with prognosis and treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If histological assessment methods (KI67 index or mitotic counts) are used for risk stratification, then the assessment process is simple and quick, but the reliability and accuracy of identifying high-risk patients is insufficient
Solution Approach 1:
The patent transitions from traditional histological parameters (KI67 index, mitotic counts) to molecular parameters (gene expression levels of BUB1B and PINK1, methylation status of G0S2). This parameter change enables more reliable risk stratification by capturing molecular characteristics that correlate with patient outcomes, while the standardized scoring system maintains practical assessability.
Solution Approach 2:
The patent replaces mechanical/histological assessment methods with molecular biology-based methods. Instead of visually evaluating tissue sections under a microscope, the invention uses gene expression analysis and methylation status determination, substituting traditional pathological techniques with molecular diagnostics to achieve superior reliability in risk prediction.
2Reliability
If adjuvant chemotherapy is administered to all post-surgical ACC patients, then high-risk patients receive necessary treatment, but low-risk patients undergo unnecessary chemotherapy with associated side effects
Solution Approach 1:
The patent applies local quality by tailoring treatment to individual patient risk profiles rather than applying a uniform treatment approach. Patients are stratified into molecular subgroups (COC1, COC2, COC3) with distinct prognoses, enabling customized adjuvant therapy decisions that match each patient's specific risk level and molecular characteristics.
Solution Approach 2:
The patent implements feedback by using molecular marker results to guide treatment decisions. The gene expression and methylation analysis provides feedback on patient risk status, which then informs whether adjuvant chemotherapy should be administered, creating a closed-loop decision-making process that optimizes treatment based on individual patient characteristics.
3Measurement precision
If molecular subgroup classification (COC1, COC2, COC3) is implemented, then accurate identification of high-risk patients is achieved, but the assessment process becomes more complex requiring multiple gene expression and methylation measurements
Solution Approach 1:
The patent merges multiple measurement components into an integrated molecular assessment system. The gene expression levels of BUB1B and PINK1, along with the methylation status of G0S2, are combined into a unified molecular subgroup classification (COC1, COC2, COC3). This consolidation achieves high measurement precision while streamlining the assessment through a comprehensive but integrated approach.
Solution Approach 2:
The patent creates a universal molecular classification system that serves multiple functions: risk stratification, prognosis prediction, and treatment guidance. The same molecular markers (BUB1B expression, PINK1 expression, G0S2 methylation) used for classification also provide prognostic information and inform therapeutic decisions, maximizing the utility of the molecular assessment.
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
The present disclosure relates to compositions, systems, and methods for characterizing cancer and determining a treatment course of action. In particular, the present disclosure relates to compositions, systems, and methods for utilizing gene expression and methylation profiles to stratify and treat adrenocortical carcinoma.